Publications by authors named "Arvindpaul Mangat"
Article Synopsis
- The study aims to assess how the size of the primary tumor in T3 N0-3M0 supraglottic cancers affects overall survival (OS) and disease-free survival (DFS) for patients treated with intensity-modulated radiotherapy (IMRT).
- This retrospective cohort analysis involved 239 patients from Canadian cancer centers, measuring tumor volume via imaging and employing survival analysis methods.
- Results indicate that larger primary tumor volume correlates with worse OS and DFS, suggesting that patients with significant tumor sizes might benefit more from surgical intervention like laryngectomy followed by radiotherapy.*
Many studies have investigated the imaging sequelae of repetitive head trauma with mixed results, particularly with regard to the detection of intracranial white matter changes (WMCs) and cerebral microhemorrhages (CMHs) on ≤3 Tesla (T) field magnetic resonance imaging (MRI). 7T MRI, which has recently been approved for clinical use, is more sensitive at detecting lesions associated with multiple neurological diagnoses. In this study, we sought to determine whether 7T MRI would detect more WMCs and CMHs than 3T MRI in 19 professional fighters, 16 patients with single TBI, versus 82 normal healthy controls (NHCs).
View Article and Find Full Text PDFAssociation of Primary Tumor Volume With Survival in Patients With T3 Glottic Cancer Treated With Radiotherapy: A Study of the Canadian Head & Neck Collaborative Research Initiative.
JAMA Otolaryngol Head Neck Surg
February 2023
Importance: The association of primary tumor volume with outcomes in T3 glottic cancers treated with radiotherapy with concurrent chemotherapy remains unclear, with some evidence suggesting worse locoregional control in larger tumors.
Objective: To evaluate the association of primary tumor volume with oncologic outcomes in patients with T3 N0-N3 M0 glottic cancer treated with primary (chemo)radiotherapy in a large multi-institutional study.
Design, Setting, And Participants: This multi-institutional retrospective cohort study involved 7 Canadian cancer centers from 2002 to 2018.